IL6 and neoplasm: Researchers used anti-IL-6 antibody (Angevin et al., 2014) and CSF-1R inhibitors (Hollmen et al., 2016) to block the monocytes recruitment into tumor tissue; others by decreasing the population of TAMs, such as anti-CD11b antibody (Zhang et al., 2015).